Article
Dr. Kamdar on the Results of the TRANSFORM Trial in Relapsed/Refractory LBCL
Author(s):
Manali Kamdar, MD, discusses the results of the phase 3 TRANSFORM trial in relapsed/refractory large B-cell lymphoma (LBCL) that were presented during the 2021 ASH Annual Meeting & Exposition.
Manali Kamdar, MD, clinical director of Lymphoma Services, associate professor in Medicine/Hematology, University of Colorado Medicine, discusses the results of the phase 3 TRANSFORM trial (NCT03575351) in relapsed/refractory large B-cell lymphoma (LBCL) that were presented during the 2021 ASH Annual Meeting & Exposition.
Interim results from the TRANSFORM trial met the primary end pointof event-free survival (EFS) at a median follow-up of 6.2 months, Kamdar says. The lisocabtagene maraleucel (Breyzani; liso-cel)–containing arm demonstrated a median EFS of 10.1 months compared with the standard of care (SOC) arm that demonstrated an EFS of only 2.3 months, Kamdar explains. Moreover, the stratified hazard ratio was 0.3, which translates to a 65% reduction in the EFS events favoring liso-cel.
When looking at the key secondary end points of the study, the complete response rate was had a statistically significantly differentand higher with liso-cel vs SOC at 66% vs 39%, respectively, Kamdar continues. Progression-free survival (PFS), another secondary end point, also favored liso-cel vs SOC. The median PFS was 14.8 months vs 5.7 months, respectively, Kamdar concludes.
